{ "abstract": "Background/Aim: Although dexamethasone (DEX) is essential for preventing chemotherapy-induced nausea and vomiting during concurrent chemoradiotherapy (CCRT) for cervical cancer, prolonged administration carries risks of adverse events. Therefore, we evaluated the effect of a shortened DEX duration (steroid-sparing therapy) on the total control (TC) of nausea and vomiting in patients with cervical cancer undergoing CCRT comprising cisplatin 40 mg/m2 to avoid the risk of adverse effects associated with DEX administration.\n\nPatients and Methods: This multicenter, retrospective study included 579 patients with cervical cancer who underwent CCRT between January 2016 and March 2024. Patients were classified into the steroid- sparing (DEX day 1; N=80) and non-steroid-sparing (DEX days 1-3; N=499) groups. TC was defined as the absence of vomiting and nausea without rescue medication during the entire CCRT period. A multivariate logistic regression analysis was used for between-group comparisons to adjust for potential confounders.\n\nResults: The baseline rate of olanzapine use was significantly higher in the steroid-sparing group [28.8% vs. 10.6% (non-steroid-sparing group); p<0.001]. TC rates during the entire CCRT period were 30.0% and 36.5% in the steroid and non-steroid-sparing groups, respectively. No statistically significant difference in the overall TC period [odds ratio (OR)=0.826; 95% confidence interval (CI)=0.480-1.420; p=0.490] was observed. Furthermore, propensity score matching analysis adjusted for olanzapine use, radiation dose, and other covariates confirmed these findings (OR=0.736; 95% CI=0.370-1.460; p=0.381). However, the TC rate during the delayed phase in the non-steroid-sparing group (71.7%) was higher than that in the steroid-sparing group (60.0%), indicating an increased risk of treatment failure (OR=0.591; p=0.035). This difference was not statistically significant after Bonferroni correction (significance threshold: p<0.0125). Furthermore, propensity score-matched univariate analysis confirmed no significant difference in the delayed phase between the two groups (p=0.243).\n\nConclusion: Steroid-sparing therapy did not compromise TC rates, suggesting that it may be a clinically acceptable option for patients undergoing CCRT. However, individualized risk assessment and appropriate antiemetic use remain essential.", "abstract_shown": true, "affiliations": [ "Department of Pharmacy, NHO Shikoku Cancer Center, Matsuyama, Japan", "Department of Clinical Pharmacy, College of Pharmaceutical Sciences, Matsuyama University, Matsuyama, Japan", "Department of Drug Safety and Risk Management, School of Pharmacy, Tokyo University of Pharmacy and Life Sciences, Hachioji, Japan", "Division of Pharmacy, Ehime University Hospital, Matsuyama, Japan", "Division of Hospital Pharmacy, Hiroshima City Hiroshima Citizens Hospital, Hiroshima, Japan", "Department of Pharmacy, Saga University Hospital, Saga, Japan", "Division of Hospital Pharmacy, Niigata University Medical and Dental Hospital, Niigata, Japan", "Division of Pharmacy, St. Marianna University Hospital, Kawasaki, Japan", "Division of Hospital Pharmacy, Tokyo Metropolitan Tama Medical Center, Fuchu, Japan", "Division of Hospital Pharmacy, Aomori Prefectural Central Hospital, Aomori, Japan", "Department of Pharmacy, Yamagata University Hospital, Yamagata, Japan", "Division of Pharmacy, Nagaoka Red Cross Hospital, Nagaoka, Japan", "Department of Pharmacy, University of Yamanashi Hospital, Chuo, Japan", "Division of Hospital Pharmacy, Nagaoka Chuo General Hospital, Nagaoka, Japan", "Division of Hospital Pharmacy, National Hospital Organization Iwakuni Clinical Center, Iwakuni, Japan", "Division of Hospital Pharmacy, National Hospital Organization Hamada Medical Center, Hamada, Japan", "Division of Pharmacy, Uonuma Kikan Hospital, Minamiuonuma, Japan" ], "article_type": "research article", "arxiv": null, "author_total": 18, "authors": [ { "affs": [ 0, 1 ], "name": "TAKUMA MATSUMOTO" }, { "affs": [ 2 ], "name": "KENSUKE YOSHIDA" }, { "affs": [ 3 ], "name": "MASAKI NAKAI" }, { "affs": [ 4 ], "name": "YUSUKE KAWAMURA" }, { "affs": [ 5 ], "name": "YOSHINOBU GOHARA" }, { "affs": [ 6 ], "name": "NAOTO HOSHINO" }, { "affs": [ 7 ], "name": "HAJIME MORITA" }, { "affs": [ 8 ], "name": "NAOYA TONOMURA" }, { "affs": [ 9 ], "name": "MANAMI BANBA" }, { "affs": [ 10 ], "name": "AYAKO YAMAGUCHI" }, { "affs": [ 11 ], "name": "MASAKI TACHIBANA" }, { "affs": [ 12 ], "name": "TOMOKI FUKUSHIMA" }, { "affs": [ 13 ], "name": "HIROKI HOSOKAWA" }, { "affs": [ 14, 15 ], "name": "TAKUYA MURA" }, { "affs": [ 16 ], "name": "TSUYOSHI YABUKI" }, { "affs": [ 3 ], "name": "NORIAKI HIDAKA" }, { "affs": [ 0 ], "name": "YASUSHI SEMBA" }, { "affs": [ 1 ], "name": "SHINICHI WATANABE" } ], "bibtex": "https://research.draconitic.com/paper/2xgk5twv9mt86.bib", "cited_by": 0, "doi": "10.21873/invivo.14513", "fulltext_url": "https://pmc.ncbi.nlm.nih.gov/articles/PMC13723993/", "id": "2xgk5twv9mt86", "issns": [ "0258-851X", "1791-7549" ], "landing_url": "https://doi.org/10.21873/invivo.14513", "language": "en", "licence": "CC-BY-NC-ND-4.0", "licence_label": "CC BY-NC-ND 4.0", "licence_source": "article", "licence_url": "https://creativecommons.org/licenses/by-nc-nd/4.0/", "metadata_licence": null, "native_subjects": [ [ "heading", "Research Article" ], [ "openalex", "2746|Nausea and vomiting management" ] ], "openalex": "W7224463016", "pdf_url": "https://iv.iiarjournals.org/content/invivo/40/6/3763.full.pdf", "pmcid": "PMC13723993", "pmid": "42957248", "published": "2026-10-29", "publisher": "International Institute of Anticancer Research", "ris": "https://research.draconitic.com/paper/2xgk5twv9mt86.ris", "sources": [ { "first_seen": "2026-11-04T12:22:32Z", "native_id": "PMC13723993", "source": "pmc", "url": "https://doi.org/10.21873/invivo.14513" } ], "subjects": [ { "field": "medicine", "origin": "openalex:2746|Nausea and vomiting management", "subfield": "surgery" } ], "title": "Incidence of Nausea and Vomiting in Patients With Cervical Cancer Undergoing Chemoradiotherapy With Steroid-Sparing", "title_text": "Incidence of Nausea and Vomiting in Patients With Cervical Cancer Undergoing Chemoradiotherapy With Steroid-Sparing", "type": "peer-reviewed", "updated_at": "2026-11-05T12:20:43Z", "url": "https://research.draconitic.com/paper/2xgk5twv9mt86", "venue": "In Vivo", "versions": [] }